Evidence map›Paper›PMID 36819182›Full record

ArticleEJHaem2023

Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10).

Hiroki Mizumaki, Ken Ishiyama, Jun Aoki, Jinichi Mori, Shohei Mizuno, Noriko Doki, Takahiro Fukuda, Naoyuki Uchida, Masahito Onizuka, Masatsugu Tanaka and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 1 country.

Hiroki MizumakiDepartment of Hematology Kanazawa University Hospital Kanazawa Japan.ORCID https://orcid.org/0000-0002-9933-4638
Ken IshiyamaDepartment of Hematology Kanazawa University Hospital Kanazawa Japan.ORCID https://orcid.org/0000-0002-6189-0620
Jun AokiDepartment of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan.
Jinichi MoriDepartment of Hematology Jyoban Hospital of Tokiwa Foundation Fukushima Japan.ORCID https://orcid.org/0000-0002-4255-5616
Shohei MizunoDivision of Hematology Department of Internal Medicine Aichi Medical University Nagakute Japan.
Noriko DokiHematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan.
Naoyuki UchidaDepartment of Hematology Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital Tokyo Japan.
Masahito OnizukaDepartment of Hematology and Oncology Tokai University School of Medicine Isehara Japan.
Masatsugu TanakaDepartment of Hematology Kanagawa Cancer Center Yokohama Japan.
Yuta KatayamaDepartment of Hematology Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital Hiroshima Japan.
Yukiyasu OzawaDepartment of Hematology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Kazuhiro IkegameDepartment of Hematology Hyogo Medical University Hospital Hyogo Japan.
Satoru TakadaLeukemia Research Center Saiseikai Maebashi Hospital Maebashi Japan.
Toshiro KawakitaDepartment of Hematology National Hospital Organization Kumamoto Medical Center Kumamoto Japan.
Nobuyuki AotsukaDivision of Hematology-Oncology Japanese Red Cross Society Narita Hospital Narita Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation Nagoya Japan.
Masamitsu YanadaDepartment of Hematology and Cell Therapy Aichi Cancer Center Nagoya Japan.
Aichi Medical University · JPKanazawa University Hospital · JPAichi Cancer Center · JPGunma Saiseikai Maebashi Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHyogo University · JPJapanese Red Cross Nagoya Daiichi Hospital · JPJapanese Red Cross Narita Hospital · JPJyoban Hospital of Tokiwa Foundation · JPKanagawa Prefectural Hospital Organization · JPKumamoto Medical Center · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of acute myeloid leukemia (AML) patients with der(1;7)(q10;p10) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) is unclear due to its rarity. We retrospectively analyzed 151 AML patients with der(1;7)(q10;p10) and compared the findings with those of 853 AML patients with monosomy 7 or chromosome 7q deletion (-7/del(7q)) using Japanese nationwide registry data. The der(1;7)(q10;p10) group showed significantly better transplant outcomes than the -7/del(7q) group. In the multivariate analysis of the der(1;7)(q10;p10) group, additional chromosomal abnormalities and a poor performance status significantly influenced the survival. In conclusion, allo-SCT is a feasible treatment option for AML patients with der(1;7)(q10;p10).

Indexed as

additional chromosomal abnormalitiesallogeneic hematopoietic stem cell transplantationAMLder(1;7)(q10;p10)

Identifiers

PMID36819182
PMCPMC9928652
OpenAlexW4308320723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.